It was reported on Wednesday that United States-based Additive Orthopaedics LLC has received approval from the United States Food and Drug Administration (FDA) for the Patient Specific Talus Spacer 3D-printed talus (ankle bone) implant for humanitarian use.
The product is a 3D printed implant that can be used in talus replacement surgery. The talus spacer is made individually for each patient, modelled from computed tomography imaging, and is fitted to a patient's specific anatomy. The Patient Specific Talus Spacer is claimed to be the first in the world and first-of-its-kind implant to replace the talus, the bone in the ankle joint that connects the leg and the foot, for the treatment of avascular necrosis (AVN) of the ankle joint, a serious and progressive condition that causes the death of bone tissue stemming from a lack of blood supply to the area.
The US FDA has reviewed data for the Patient Specific Talus Spacer via the humanitarian device exemption process.
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion
BioCryst wins FDA approval for oral HAE prophylaxis in young children
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment